- Pfizer released data Nov. 22 showing its COVID-19 vaccine was 100 percent effective at preventing disease among recipients ages 12-15, measured from seven days to four months after they received their second shot.
- A study published Dec. 1 in The New England Journal of Medicine showed that Moderna’s COVID-19 vaccine was slightly more effective than Pfizer’s at preventing disease and subsequent negative outcomes among U.S. veterans.
- A study published Dec. 2 in The Lancet showed that the COVID-19 vaccines made by Pfizer and Moderna are most effective at boosting antibody levels among fully vaccinated adults.
- A small study published Dec. 5 in the preprint server MedRxiv showed that people who received two doses of Pfizer’s COVID-19 vaccine might get the same increase in immunity from a Johnson & Johnson booster dose as one from Pfizer.
- Pfizer said Dec. 8 its COVID-19 booster provided significant protection against the omicron variant during a laboratory study.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
